Halozyme Therapeutics, Inc. (HALO) Misses Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq futures slide as Alphabet results intensify AI spending fears
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Oil falls as diplomacy hopes outweigh Middle East escalation fears
- SK Hynix shares surge after Q3 profit beats expectations
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $130.03 --0%
EPS Growth %: +32.6%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
CCB, ESCA, MPT, More
EPS Growth %: +32.6%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
CCB, ESCA, MPT, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q1 EPS of ($0.14), $0.03 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $7.4 million versus the consensus estimate of $7.31 million.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Allegheny Technologies (ATI) Tops Q3 EPS by 9c ; Offers Guidance
- Sirius XM (SIRI) Tops Q3 EPS by 1c
- Crocs (CROX) Tops Q3 EPS by 39c; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
